Antiarrhythmic Drugs — Vaughan Williams Mechanisms, ECG Effects and Adverse Reactions

The classical Vaughan Williams classification organises antiarrhythmic drugs by their dominant electrophysiological action. It is a framework for connecting an ion current or autonomic effect to conduction, refractoriness and an ECG change. It does not establish the best treatment for every patient with an arrhythmia. The rhythm, haemodynamic state, underlying heart disease, renal function and interacting drugs all influence the actual choice.

Adenosine, digoxin and magnesium are commonly discussed alongside these classes but do not fit neatly into the original table. Some teaching schemes call them miscellaneous or class V. Modern expanded classifications use a more detailed system, so class V is not a universal synonym for all miscellaneous agents. In an exam asking for the traditional Vaughan Williams scheme, begin with the original classes I–IV.

In atrial and ventricular working myocardium and Purkinje tissue, the rapid phase 0 upstroke depends largely on fast sodium entry. Class I drugs reduce this upstroke and slow conduction in these tissues. Repolarisation during phase 3 involves outward potassium currents; class III agents prolong this recovery phase and the refractory period. The plateau includes calcium entry balanced against outward currents.

SA and AV nodal cells behave differently. Their action-potential upstroke depends predominantly on calcium entry, rather than the same rapid sodium current used by working ventricular muscle. Spontaneous diastolic depolarisation drives automaticity. Beta blockers reduce adrenergic acceleration of nodal activity, while verapamil and diltiazem slow calcium-dependent AV nodal conduction. This explains why nodal drugs are useful in selected supraventricular rhythms.

On the ECG, QRS widening can reflect slowed ventricular conduction, while QT prolongation reflects delayed overall ventricular depolarisation and repolarisation. PR prolongation is a useful clue to slowed AV conduction. These associations are not interchangeable. When interpreting a drug effect, identify the tissue and the process first, then the interval likely to change.

All class I drugs block fast sodium channels, but they differ in the degree of conduction slowing and their effects on action-potential duration. Ia agents have moderate sodium blockade and also prolong repolarisation. Ib agents have relatively modest effects on normal fast-tissue conduction and shorten the action potential. Ic agents produce marked conduction slowing with comparatively little direct effect on action-potential duration.

For an exam asking which sodium-channel-blocker subclass shortens action-potential duration, select Ib. If the stem emphasises marked conduction slowing without much direct repolarisation effect, select Ic. Do not write that class Ic drugs have no ECG effect: flecainide can widen the QRS substantially. A measured QT can change when depolarisation lengthens, even without a primary class III-like repolarisation effect.

Lidocaine and mexiletine are principally associated with ventricular arrhythmias rather than routine atrial-fibrillation conversion. Flecainide and propafenone can be used in selected supraventricular arrhythmias, but structural or ischaemic heart disease changes their suitability. Flecainide is not a routine answer for a patient with prior myocardial infarction or heart failure merely because the rhythm could respond to sodium blockade.

Class II drugs are beta blockers. They reduce the effects of sympathetic stimulation on cardiac automaticity and AV nodal conduction. Examples include propranolol, metoprolol and esmolol. In selected atrial fibrillation or flutter, slowing conduction through the AV node reduces the ventricular response. This is rate control; it does not necessarily restore sinus rhythm or stop the atrial arrhythmia.

Class IV drugs are the non-dihydropyridine calcium-channel blockers verapamil and diltiazem. Their effect on calcium-dependent nodal tissue slows AV conduction and increases nodal refractoriness. They may be used for selected supraventricular tachycardias and for ventricular-rate control in atrial fibrillation or flutter. Amlodipine and nifedipine are not the standard class IV antiarrhythmic examples because their clinical actions are mainly vascular.

Bradycardia, hypotension or pre-existing conduction disease can make nodal-slowing drugs inappropriate. Nonselective beta blockers are contraindicated in bronchial asthma, and acute decompensated heart failure is an important contraindication to beta-blocker administration in this setting. Combining nodal blockers can amplify conduction suppression. For verapamil and diltiazem, impaired ventricular function also needs particular consideration. The rhythm matters: AV nodal blockade is not an indiscriminate answer for every rapid rhythm, especially when accessory-pathway conduction is involved.

Class III drugs primarily block potassium channels and prolong repolarisation and the effective refractory period. Their classic ECG association is QT prolongation. Examples include amiodarone, sotalol, dofetilide and ibutilide. Delayed repolarisation can increase the risk of torsades de pointes, particularly in a susceptible patient or in the presence of electrolyte disturbance or other QT-prolonging medicines.

Amiodarone has multiple actions, including sodium-channel, calcium-channel and antiadrenergic effects in addition to its class III properties. It is useful in several atrial and ventricular arrhythmia settings, but its extracardiac toxicity distinguishes it from a simple potassium-channel blocker. It has a long elimination time, so drug effects and interactions can persist after it is discontinued.

• Pulmonary toxicity, often with an interstitial pattern.
• Thyroid dysfunction, which can be hypothyroid or hyperthyroid.
• Hepatic injury and abnormal liver function.
• Corneal microdeposits and possible visual symptoms.
• Photosensitivity and blue-grey skin discoloration.
• Bradycardia, conduction effects and clinically important drug interactions.

Amiodarone prolongs QT but has a lower tendency to cause torsades than many other repolarisation-prolonging agents, particularly during chronic oral use. The risk is not zero, especially with IV administration or additional risk factors. Sotalol combines class II beta blockade with class III action, so both bradycardia and QT-associated proarrhythmia are relevant.

Adenosine activates adenosine receptors in nodal tissue, increases outward potassium current and reduces calcium-dependent activity. The resulting transient AV nodal block can terminate an AV-node-dependent re-entry circuit. Its clinical role is therefore mechanistic: it is particularly useful in an appropriate regular supraventricular tachycardia, rather than being a general treatment for every tachycardia.

Adenosine has a very short duration and is administered rapidly through suitable IV access with monitoring. Flushing, chest discomfort, dyspnoea and a brief conduction pause can occur. Active bronchospasm is a contraindication. Caffeine and theophylline antagonise its effects. Avoid treating an irregular or polymorphic wide-complex tachycardia as a routine adenosine-responsive rhythm; accessory pathways can make AV nodal blockade hazardous.

Digoxin inhibits Na/K-ATPase and increases cardiac contractility, while its vagal action slows AV conduction. It can have a role in selected rate-control settings, including some patients with heart failure, but is not usually the first-line choice for all atrial fibrillation. Toxicity can produce gastrointestinal symptoms, neurological or visual disturbances and a range of arrhythmias. Atrial tachycardia with AV block is a classic recognition pattern.

Magnesium is central to the management of torsades de pointes. Treatment also addresses the causative drug and relevant electrolyte abnormalities. Magnesium does not become a standard class I–IV drug simply because it treats an arrhythmia. Its use illustrates the limit of the traditional classification: an appropriate treatment can lie outside the four main pharmacological groups.

A drug can suppress one rhythm while provoking another. This proarrhythmic potential is the main reason classification cannot be used as a stand-alone prescribing rule. QT-associated risk is affected by patient factors, interacting medicines and electrolytes. Conduction-slowing drugs can instead produce marked QRS widening or block. The ECG interval that changes should direct the next question about mechanism and risk.

For toxicity vignettes, start with the distinctive symptom cluster rather than a single nonspecific symptom. Tinnitus with visual symptoms suggests cinchonism; lupus-like illness suggests procainamide; lung and thyroid findings suggest amiodarone. Lidocaine toxicity can begin with neurological warning symptoms. The drug history and route of administration help distinguish an adverse effect from the presenting arrhythmia.

Read stability before the drug class. Resuscitation Council UK guidance identifies electrical cardioversion as the preferred treatment for an unstable tachyarrhythmia with life-threatening adverse signs. A pulseless arrest is managed through the arrest algorithm. A memorised pharmacology table must not delay the appropriate electrical or resuscitation intervention.

1. Identify whether the patient has a pulse and whether there are life-threatening adverse signs.
2. Characterise rhythm regularity and QRS width, and consider accessory-pathway conduction.
3. Determine whether the objective is rate control, rhythm conversion or prevention of recurrence.
4. Check for structural/ischaemic disease, impaired ventricular function, conduction disease and relevant comorbidities.
5. Consider QT/QRS/PR effects, electrolytes, renal clearance and interacting drugs.
6. Then connect the selected option to its dominant mechanism and characteristic adverse effect.

A regular AV-node-dependent supraventricular tachycardia supports consideration of adenosine in the right setting. Stable atrial fibrillation requiring rate control points towards suitable nodal agents. A prior myocardial infarction should make routine flecainide selection unattractive. Polymorphic ventricular tachycardia associated with prolonged QT points towards torsades management rather than reflexively adding another QT-prolonging drug.